International journal of molecular sciencesOct 16, 2026

How Activating GLP-1, GIP, and Glucagon Receptors May Link Obesity and Brain Degeneration

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 17, 2026

Abstract

Glucagon-like peptide-1 receptor agonism may influence neurodegenerative processes through metabolic and inflammatory pathways.

Preclinical findings suggest modulation of insulin signaling, synaptic function, mitochondrial health, and neuroinflammation.
In Alzheimer's disease, liraglutide failed to meet its primary trial endpoint, and semaglutide did not slow disease progression.
Parkinson's disease trials produced mixed results without demonstrating disease modification.
Observational studies indicate potential associations with reduced dementia risk, but these findings may be affected by confounding factors.
Evidence for tirzepatide and retatrutide is mainly from observational or preclinical studies.
Greater metabolic efficacy of these compounds does not guarantee neuroprotection, and nutritional factors may limit their therapeutic use.

Simplified

Glucagon-like peptide-1 receptor agonism has attracted interest in neurodegeneration because of its effects on metabolic and inflammatory pathways implicated in neuronal dysfunction. This narrative review examines the molecular rationale and neurological evidence for selective glucagon-like peptide-1 receptor agonists, dual agonists additionally targeting the glucose-dependent insulinotropic polypeptide receptor, and triple agonists also engaging the glucagon receptor. English-language literature retrieved from PubMed, Scopus, and Web of Science was synthesized according to study design and neurological relevance. Preclinical findings indicate modulation of insulin signaling, synaptic function, mitochondrial homeostasis, and neuroinflammation, but responses vary across compounds and experimental models. In Alzheimer's disease, liraglutide did not meet its primary trial endpoint, and semaglutide did not slow clinical progression. Parkinson's disease trials have yielded mixed results without establishing disease modification. Observational associations with reduced dementia risk remain susceptible to confounding. Neurological evidence for tirzepatide and retatrutide remains predominantly observational or preclinical. Greater metabolic efficacy does not establish neuroprotection, while nutritional vulnerability may constrain therapeutic applicability. Dedicated randomized trials integrating clinical outcomes with pharmacological exposure, target engagement, and metabolic mediation are required to distinguish systemic effects from direct neural actions and determine whether these therapies can prevent cognitive decline or modify established neurodegenerative disease.

Full Text

Full text is available at the source.

View Full Text ↗

Featured in

GLP-1 TherapiesIssue #59

GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes

↗

How Activating GLP-1, GIP, and Glucagon Receptors May Link Obesity and Brain Degeneration

Abstract

Full Text

Featured in

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief